Biosig Technologies (NASDAQ:STEX) Chairman Morgan Lee Lekstrom Purchases 50,000 Shares

Biosig Technologies, Inc. (NASDAQ:STEX) Chairman Morgan Lee Lekstrom purchased 50,000 shares of the business’s stock in a transaction on Friday, June 12th. The stock was purchased at an average cost of $0.99 per share, for a total transaction of $49,500.00. Following the acquisition, the chairman owned 359,500 shares in the company, valued at approximately $355,905. The trade was a 16.16% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Morgan Lee Lekstrom also recently made the following trade(s):

• On Thursday, May 28th, Morgan Lee Lekstrom purchased 34,000 shares of Biosig Technologies stock. The stock was purchased at an average cost of $1.47 per share, for a total transaction of $49,980.00.
• On Thursday, May 21st, Morgan Lee Lekstrom bought 147,000 shares of Biosig Technologies stock. The stock was bought at an average cost of $1.04 per share, with a total value of $152,880.00.
• On Tuesday, April 14th, Morgan Lee Lekstrom sold 12,759 shares of Biosig Technologies stock. The stock was sold at an average price of $1.07, for a total transaction of $13,652.13.

Biosig Technologies Stock Performance

NASDAQ:STEX opened at $1.01 on Tuesday. The stock has a 50-day moving average of $1.07. Biosig Technologies, Inc. has a 12 month low of $0.70 and a 12 month high of $14.11. The stock has a market cap of $183.62 million, a PE ratio of -0.10 and a beta of 1.84.

Biosig Technologies (NASDAQ:STEX) last posted its earnings results on Thursday, May 14th. The company reported ($0.27) EPS for the quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Weiss Ratings raised shares of Biosig Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 1st. Wall Street Zen cut shares of Biosig Technologies from a “hold” rating to a “strong sell” rating in a research report on Sunday, April 5th. Finally, Needham & Company LLC dropped their target price on shares of Biosig Technologies from $9.00 to $8.00 and set a “buy” rating for the company in a research report on Thursday, May 21st. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $8.00.

Biosig Technologies Company Profile

Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.